Paclitaxel (TAXOL®) concentrations in brain tumor tissue

134Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Paclitaxel (Taxol®) is a novel chemotherapeutic agent, active against a variety of tumors. It is not known whether the drug penetrates brain tumor tissue. Patients and methods: Three patients with a recurrent glioma received paclitaxel (175 mg/m2) in a 3-hour i.v. infusion prior to surgery. Paclitaxel concentrations were measured in the tumor tissue, cerebrospinal fluid, cyst fluid, plasma and, in one patient, normal brain tissue. Results: Tumor tissue concentrations were in the thera- peutic range in all three patients. Brain tissue concentration, however, was below the detection limit of the trial. Conclusions: These findings suggest that paclitaxel may have a place in brain tumor therapy. The low concentration in normal brain tissue, as observed in one patient, may suggest, however, that the drug does not cross the intact blood-brain barrier. © 1994 Kluwer Academic Publishers.

Cite

CITATION STYLE

APA

Heimans, J. J., Vermorken, J. B., Wolbers, J. G., Eeltink, C. M., Meijer, O. W. M., Taphoorn, M. J. B., & Beijnen, J. H. (1994). Paclitaxel (TAXOL®) concentrations in brain tumor tissue. Annals of Oncology, 5(10), 951–953. https://doi.org/10.1093/oxfordjournals.annonc.a058736

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free